Isotechnika and Hoffmann-La Roche Enter Drug Development Deal

Edmonton-based Isotechnika Inc., a biotechnical company, and Swiss drug company Hoffmann-La Roche Ltd. entered a drug development deal on April 9, 2002. Under terms of the agreement, Isotechnika is to receive up to US$215 million from Hoffmann-La Roche in a global co-development accord covering Isotechnika’s novel drug, ISAtx247, which helps patients fight organ rejection following a transplant. Hoffmann-La Roche will cover 70 per cent of the development costs for ISAtx247, now in phase two clinical trials. In exchange, Hoffmann-La Roche will gain exclusive marketing rights to the product worldwide. The partners have agreed to handle future development of the drug jointly.

Isotechnika was represented in-house by Joseph Koziak, executive vice-president and counsel in Scottsdale, Arizona; and externally by Douglas Goss, Q.C., of Bryan & Company in Edmonton; Lawrence Meyer (antitrust) in Potomac, Maryland; Kathleen Keller-Hobson, Wendy Gross, Sherri Kreisman and Vanessa Grant (special counsel) of Torys LLP in Toronto; and Mary Ann Dillahunty (patents) of Burns Doane in California.

Hoffman-La Roche was represented by in-house counsel Carol Nuechterlein (corporate finance) in Basel, Switzerland; and Robert Silverman, Peter Paciorek and Gerald Bohm (patents) in New Jersey. In Canada, Hoffmann-La Roche was represented by in-house counsel James Willoughby, and external counsel Gowling Lafleur Henderson LLP with a team comprised of Grant Sawiak and Charmaine Chung (securities) in Toronto and William Vanveen (competition) and Henry Brown (Investment Canada) in Ottawa.


Charmaine Chung Sherri Baker Henry S. Brown William L. Vanveen Douglas O. Goss Grant Victor Sawiak Wendy J. Gross Vanessa Grant Fae J. Shaw Mary Ann Dillahunty


Bryan & Company LLP Torys LLP Burns, Doane, Swecker & Mathis LLP Gowling WLG Gowling WLG